ALUNBRIG® (brigatinib) Expert Opinion Video Series: Impact of brain metastases on patients with ALK+ aNSCLC and ALUNBRIG quality of life (QOL) data from the ALTA-1L study
Prescribing information is available at the top of the page.
Listen to Dr Yvonne Summers discuss the current unmet needs of patients with ALK+ aNSCLC, including the negative impact of brain metastases on the daily lives of these patients.
Dr Summers provides an overview of the ALUNBRIG health-related QOL data from the ALTA-1L study in patients with ALK+ aNSCLC and how these results compare with her real-world experience in clinical practice.
Dr Summers also highlights the importance of the once daily ALUNBRIG dosing regimen to help reduce treatment burden in patients with ALK+ aNSCLC.
ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; aNSCLC, advanced non-small cell lung cancer; QOL, quality of life.
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
